These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1549225)

  • 1. 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients.
    Weissman JD; Constantinitis I; Hudgins P; Wallace DC
    Neurology; 1992 Mar; 42(3 Pt 1):619-23. PubMed ID: 1549225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy.
    Sinnwell TM; Sivakumar K; Soueidan S; Jay C; Frank JA; McLaughlin AC; Dalakas MC
    J Clin Invest; 1995 Jul; 96(1):126-31. PubMed ID: 7615782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.
    Pezeshkpour G; Illa I; Dalakas MC
    Hum Pathol; 1991 Dec; 22(12):1281-8. PubMed ID: 1748434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions.
    Lane RJ; McLean KA; Moss J; Woodrow DF
    Neuropathol Appl Neurobiol; 1993 Oct; 19(5):406-13. PubMed ID: 8278024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis in AZT myopathy.
    Chalmers AC; Greco CM; Miller RG
    Neurology; 1991 Aug; 41(8):1181-4. PubMed ID: 1714057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV or zidovudine myopathy?
    Gherardi R; Chariot P
    Neurology; 1994 Feb; 44(2):361-2; author reply 362-4. PubMed ID: 8309597
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV or zidovudine myopathy?
    Dalakas M
    Neurology; 1994 Feb; 44(2):360-1; author reply 362-4. PubMed ID: 8309594
    [No Abstract]   [Full Text] [Related]  

  • 8. Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine.
    Schröder JM; Bertram M; Schnabel R; Pfaff U
    Acta Neuropathol; 1992; 85(1):39-47. PubMed ID: 1285495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy.
    Scruggs ER; Dirks Naylor AJ
    Pharmacology; 2008; 82(2):83-8. PubMed ID: 18504416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.
    Mhiri C; Baudrimont M; Bonne G; Geny C; Degoul F; Marsac C; Roullet E; Gherardi R
    Ann Neurol; 1991 Jun; 29(6):606-14. PubMed ID: 1892364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zidovudine exposure in HIV-1 infected Tanzanian women increases mitochondrial DNA levels in placenta and umbilical cords.
    Kunz A; von Wurmb-Schwark N; Sewangi J; Ziske J; Lau I; Mbezi P; Theuring S; Hauser A; Dugange F; Katerna A; Harms G
    PLoS One; 2012; 7(7):e41637. PubMed ID: 22848552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins.
    de la Asunción JG; del Olmo ML; Sastre J; Millán A; Pellín A; Pallardó FV; Viña J
    J Clin Invest; 1998 Jul; 102(1):4-9. PubMed ID: 9649550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle involvement in HIV-infected patients.
    Gherardi RK
    Neuropathol Appl Neurobiol; 1994 Jun; 20(3):232-7. PubMed ID: 7936072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine.
    Herzberg NH; Zorn I; Zwart R; Portegies P; Bolhuis PA
    Muscle Nerve; 1992 Jun; 15(6):706-10. PubMed ID: 1324428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle.
    Pipinos II; Shepard AD; Anagnostopoulos PV; Katsamouris A; Boska MD
    J Vasc Surg; 2000 May; 31(5):944-52. PubMed ID: 10805885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial myopathy caused by long-term zidovudine therapy.
    Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
    N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro.
    Semino-Mora MC; Leon-Monzon ME; Dalakas MC
    Lab Invest; 1994 Jul; 71(1):102-12. PubMed ID: 7518879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria.
    Lewis W; Gonzalez B; Chomyn A; Papoian T
    J Clin Invest; 1992 Apr; 89(4):1354-60. PubMed ID: 1556193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine expression in the muscle of HIV-infected patients: evidence for interleukin-1 alpha accumulation in mitochondria of AZT fibers.
    Gherardi RK; Florea-Strat A; Fromont G; Poron F; Sabourin JC; Authier J
    Ann Neurol; 1994 Nov; 36(5):752-8. PubMed ID: 7979221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells.
    d'Amati G; Lewis W
    Lab Invest; 1994 Dec; 71(6):879-84. PubMed ID: 7528833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.